Monoamine Reuptake Inhibitors in Parkinson’s Disease
Joint Authors
Huot, Philippe
Fox, Susan H.
Brotchie, Jonathan M.
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-71, 71 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-02-25
Country of Publication
Egypt
No. of Pages
71
Main Subjects
Abstract EN
The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum.
However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons.
Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD.
However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents.
This review article summarises all of the available literature on use of 50 MAUIs in PD.
The compounds are divided according to their relative potency for each of the monoamine transporters.
Despite wide discrepancy in the methodology of the studies reviewed, the following conclusions can be drawn: (1) selective serotonin transporter (SERT), selective noradrenaline transporter (NET), and dual SERT/NET inhibitors are effective against PD depression; (2) selective dopamine transporter (DAT) and dual DAT/NET inhibitors exert an anti-Parkinsonian effect when administered as monotherapy but do not enhance the anti-Parkinsonian actions of L-3,4-dihydroxyphenylalanine (L-DOPA); (3) dual DAT/SERT inhibitors might enhance the anti-Parkinsonian actions of L-DOPA without worsening dyskinesia; (4) triple DAT/NET/SERT inhibitors might exert an anti-Parkinsonian action as monotherapy and might enhance the anti-Parkinsonian effects of L-DOPA, though at the expense of worsening dyskinesia.
American Psychological Association (APA)
Huot, Philippe& Fox, Susan H.& Brotchie, Jonathan M.. 2015. Monoamine Reuptake Inhibitors in Parkinson’s Disease. Parkinson’s Disease،Vol. 2015, no. 2015, pp.1-71.
https://search.emarefa.net/detail/BIM-1075904
Modern Language Association (MLA)
Huot, Philippe…[et al.]. Monoamine Reuptake Inhibitors in Parkinson’s Disease. Parkinson’s Disease No. 2015 (2015), pp.1-71.
https://search.emarefa.net/detail/BIM-1075904
American Medical Association (AMA)
Huot, Philippe& Fox, Susan H.& Brotchie, Jonathan M.. Monoamine Reuptake Inhibitors in Parkinson’s Disease. Parkinson’s Disease. 2015. Vol. 2015, no. 2015, pp.1-71.
https://search.emarefa.net/detail/BIM-1075904
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1075904